Evolution of HER2-low expression from primary to recurrent breast cancerFederica Miglietta, Maria Vittoria Dieci, Ottavia Amato et al.|npj Breast Cancer|2021Cited by 226
HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatmentFederica Miglietta, Maria Vittoria Dieci, Gaia Griguolo et al.|npj Breast Cancer|2022Cited by 100
Author Correction: Evolution of HER2-low expression from primary to recurrent breast cancerFederica Miglietta, Maria Vittoria Dieci, Gaia Griguolo et al.|npj Breast Cancer|2021Cited by 8
4MO_PR HER2-low breast cancer: Evolution from primary breast cancer to relapseFederica Miglietta, Maria Vittoria Dieci, Gaia Griguolo et al.|Annals of Oncology|2021Cited by 1
212P HER2-low breast cancer: Evolution from primary tumor to residual disease after neoadjuvant treatmentFederica Miglietta, Maria Vittoria Dieci, Gaia Griguolo et al.|Annals of Oncology|2021Cited by 0